Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison. (2026). SKIN The Journal of Cutaneous Medicine, 10(2), s738. https://doi.org/10.25251/0bwr4a20